{"altmetric_id":3086080,"counts":{"readers":{"mendeley":36,"citeulike":0,"connotea":0},"news":{"unique_users_count":1,"unique_users":["medscape"],"posts_count":2},"total":{"posts_count":12},"twitter":{"unique_users_count":10,"unique_users":["m0370","philtalamo","CancerMedMDA","UESSRR","cancerpanels","ugcfarmacg","gedefo_sefh","anagasa91","recnac1","GoToPER"],"posts_count":10}},"selected_quotes":["Bevacizumab beyond progression in mCRC: Validation of TML study (Bev beyond progression in mCRC) #SWOGOnc #JAMAOnc","Continuation or reintroduction of bevacizumab beyond progression to 1st line therapy in mCCR: BEBYP trial","Bevacizumab beyond progression to 1st-line therapy in metastatic colorectal cancer: final results of BEBYP trial"],"citation":{"abstract":"The combination of bevacizumab with fluorouracil-based chemotherapy is a standard first-line treatment option in metastatic colorectal cancer. We studied the efficacy of continuing or reintroducing bevacizumab in combination with second-line chemotherapy after progression to bevacizumab-based first-line therapy.","abstract_source":"pubmed","altmetric_jid":"4f6fa4e83cf058f610002280","authors":["G Masi","L Salvatore","L Boni","F Loupakis","C Cremolini","L Fornaro","M Schirripa","S Cupini","C Barbara","V Safina","C Granetto","E Fea","L Antonuzzo","C Boni","G Allegrini","S Chiara","D Amoroso","A Bonetti","A Falcone","G. Masi","L. Salvatore","L. Boni","F. Loupakis","C. Cremolini","L. Fornaro","M. Schirripa","S. Cupini","C. Barbara","V. Safina","C. Granetto","E. Fea","L. Antonuzzo","C. Boni","G. Allegrini","S. Chiara","D. Amoroso","A. Bonetti","A. Falcone","Masi, G.","Salvatore, L.","Boni, L.","Loupakis, F.","Cremolini, C.","Fornaro, L.","Schirripa, M.","Cupini, S.","Barbara, C.","Safina, V.","Granetto, C.","Fea, E.","Antonuzzo, L.","Boni, C.","Allegrini, G.","Chiara, S.","Amoroso, D.","Bonetti, A.","Falcone, A."],"doi":"10.1093\/annonc\/mdv012","first_seen_on":"2015-01-21T11:31:10+00:00","funders":["niehs"],"issns":["1569-8041","0923-7534"],"issue":"4","journal":"Annals of Oncology","last_mentioned_on":1490195697,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25600568?dopt=Abstract&utm_medium=twitter","http:\/\/annonc.oxfordjournals.org\/content\/early\/2015\/01\/18\/annonc.mdv012.long","http:\/\/annonc.oxfordjournals.org\/content\/early\/2015\/02\/10\/annonc.mdv012.short?rss=1","http:\/\/annonc.oxfordjournals.org\/content\/26\/4\/724.abstract","http:\/\/annonc.oxfordjournals.org\/content\/26\/4\/724.long","https:\/\/academic.oup.com\/annonc\/article-lookup\/doi\/10.1093\/annonc\/mdv012"],"pdf_url":"https:\/\/academic.oup.com\/annonc\/article-pdf\/26\/4\/724\/5121222\/mdv012.pdf","pmid":"25600568","pubdate":"2015-01-18T00:00:00+00:00","publisher":"Oxford University Press","publisher_subjects":[{"name":"Oncology And Carcinogenesis","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["neoplasms"],"title":"Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial","type":"article","uri":"https:\/\/academic.oup.com\/annonc\/article-lookup\/doi\/10.1093\/annonc\/mdv012","volume":"26","mendeley_url":"http:\/\/www.mendeley.com\/research\/continuation-reintroduction-bevacizumab-beyond-progression-firstline-therapy-metastatic-colorectal-c"},"altmetric_score":{"score":14.8,"score_history":{"1y":7,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":14.8},"context_for_score":{"all":{"total_number_of_other_articles":8396916,"mean":7.0724322720827,"rank":591778,"this_scored_higher_than_pct":92,"this_scored_higher_than":7804417,"rank_type":"exact","sample_size":8396916,"percentile":92},"similar_age_3m":{"total_number_of_other_articles":241785,"mean":8.1757104440328,"rank":21219,"this_scored_higher_than_pct":91,"this_scored_higher_than":220535,"rank_type":"exact","sample_size":241785,"percentile":91},"this_journal":{"total_number_of_other_articles":3607,"mean":9.7553044925125,"rank":383,"this_scored_higher_than_pct":89,"this_scored_higher_than":3223,"rank_type":"exact","sample_size":3607,"percentile":89},"similar_age_this_journal_3m":{"total_number_of_other_articles":150,"mean":6.1506577181208,"rank":12,"this_scored_higher_than_pct":92,"this_scored_higher_than":138,"rank_type":"exact","sample_size":150,"percentile":92}}},"demographics":{"poster_types":{"member_of_the_public":9,"researcher":1},"users":{"twitter":{"cohorts":{"Members of the public":9,"Scientists":1}},"mendeley":{"by_status":{"Unspecified":2,"Professor > Associate Professor":1,"Researcher":10,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":5,"Student  > Postgraduate":2,"Other":10,"Student  > Master":3,"Student  > Bachelor":1,"Lecturer":1},"by_discipline":{"Medicine and Dentistry":25,"Immunology and Microbiology":1,"Agricultural and Biological Sciences":4,"Business, Management and Accounting":1,"Unspecified":3,"Pharmacology, Toxicology and Pharmaceutical Science":2}}},"geo":{"twitter":{"JP":1,"US":3,"GI":1,"ES":1},"mendeley":{"BR":1,"FR":1}}},"posts":{"twitter":[{"url":"https:\/\/twitter.com\/m0370\/status\/588007164465123328","license":"datasift","citation_ids":[3086080],"posted_on":"2015-04-14T15:53:27+00:00","author":{"name":"\u30ec\u70b9","image":"https:\/\/pbs.twimg.com\/profile_images\/875739533626589184\/-KDWLx7T_normal.jpg","description":"\u304c\u3093\u75c5\u68df\u306e\u767d\u8863\u306e\u5929\u4f7f","id_on_source":"m0370","tweeter_id":"6630502","geo":{"lt":35.6895,"ln":139.69171,"country":"JP"},"followers":9876},"tweet_id":"588007164465123328"},{"url":"https:\/\/twitter.com\/philtalamo\/status\/557868646799007745","license":"datasift","rt":["GoToPER"],"citation_ids":[3086080],"posted_on":"2015-01-21T11:53:44+00:00","author":{"name":"Phil Talamo","image":"https:\/\/pbs.twimg.com\/profile_images\/558719780366991360\/3yl2SAIZ_normal.jpeg","description":"President of PER. Oncology Expert. Sports Enthusiast. Tweets are my own. #PlayFamously #LiveFamously","id_on_source":"philtalamo","tweeter_id":"572712969","geo":{"lt":43.00035,"ln":-75.4999,"country":"US"},"followers":469},"tweet_id":"557868646799007745"},{"url":"https:\/\/twitter.com\/CancerMedMDA\/status\/560559718150594560","license":"datasift","rt":["recnac1"],"citation_ids":[3086080],"posted_on":"2015-01-28T22:07:06+00:00","author":{"name":"Cancer Medicine","url":"http:\/\/www.mdanderson.org\/cancermedicine","image":"https:\/\/pbs.twimg.com\/profile_images\/876836086554677249\/pl7C_g0f_normal.jpg","description":"Mission of largest MD Anderson division is to eliminate cancer via best, integrated patient care, research & education programs. Appts.available 877-632-6789.","id_on_source":"CancerMedMDA","tweeter_id":"851503992","geo":{"lt":29.76328,"ln":-95.36327,"country":"US"},"followers":3399},"tweet_id":"560559718150594560"},{"url":"https:\/\/twitter.com\/UESSRR\/status\/560560303516422145","license":"datasift","rt":["recnac1"],"citation_ids":[3086080],"posted_on":"2015-01-28T22:09:25+00:00","author":{"name":"Yocto-domtado","image":"https:\/\/pbs.twimg.com\/profile_images\/471832229832704000\/G2ag7H_i_normal.jpeg","id_on_source":"UESSRR","tweeter_id":"156634139","geo":{"lt":null,"ln":null},"followers":352},"tweet_id":"560560303516422145"},{"url":"https:\/\/twitter.com\/cancerpanels\/status\/560567422621872128","license":"datasift","rt":["recnac1"],"citation_ids":[3086080],"posted_on":"2015-01-28T22:37:43+00:00","author":{"name":"Jim Martell","url":"http:\/\/www.CANCERPANELS.com","image":"https:\/\/pbs.twimg.com\/profile_images\/555134177339641856\/sP_Q0jY4_normal.jpeg","description":"Providing personalized cancer panels with world-leading & renowned oncology experts to cancer patients. Panels are empowering in finding BEST treatment options.","id_on_source":"cancerpanels","tweeter_id":"1402568623","geo":{"lt":null,"ln":null},"followers":132},"tweet_id":"560567422621872128"},{"url":"https:\/\/twitter.com\/ugcfarmacg\/status\/566146305601576961","license":"datasift","citation_ids":[3086080],"posted_on":"2015-02-13T08:06:12+00:00","author":{"name":"UGCFarmacia Hosp. CG","image":"https:\/\/pbs.twimg.com\/profile_images\/459257567349194752\/TuuOfpsS_normal.jpeg","description":"UGC de Farmacia \u00c1rea Sanitaria Campo de Gibraltar","id_on_source":"ugcfarmacg","tweeter_id":"398654822","geo":{"lt":36.13333,"ln":-5.35,"country":"GI"},"followers":499},"tweet_id":"566146305601576961"},{"url":"https:\/\/twitter.com\/gedefo_sefh\/status\/566554275611172864","license":"datasift","citation_ids":[3086080],"posted_on":"2015-02-14T11:07:20+00:00","author":{"name":"GEDEFO","url":"http:\/\/www.sefh.es","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000753799388\/8561701cfcfbc3a7efa7ec153101b2ab_normal.jpeg","description":"Grupo de Farmacia Oncol\u00f3gica de la SEFH","id_on_source":"gedefo_sefh","tweeter_id":"2184775389","geo":{"lt":39.5,"ln":-3,"country":"ES"},"followers":2001},"tweet_id":"566554275611172864"},{"url":"https:\/\/twitter.com\/anagasa91\/status\/566573236654059520","license":"datasift","rt":["gedefo_sefh"],"citation_ids":[3086080],"posted_on":"2015-02-14T12:22:40+00:00","author":{"name":"Ana gago","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000466462001\/47980fa38ac77e8742183cf5c1ed7df3_normal.jpeg","id_on_source":"anagasa91","tweeter_id":"1030269535","geo":{"lt":null,"ln":null},"followers":63},"tweet_id":"566573236654059520"},{"url":"https:\/\/twitter.com\/recnac1\/status\/560158796266209280","license":"datasift","citation_ids":[3086080],"posted_on":"2015-01-27T19:33:58+00:00","author":{"name":"Lee Ellis","url":"http:\/\/faculty.mdanderson.org\/Lee_Ellis\/Default.asp?SNID=0","image":"https:\/\/pbs.twimg.com\/profile_images\/378800000059398712\/de7ac036c71d31c45a708fb6530ee833_normal.jpeg","description":"Physician\/scientist at MD Anderson Cancer Ctr. Vice-Chair- SWOG Translational Medicine. Past Chair ASCO Can Res Comm. Deputy Editor JAMA Onc, Tweets are my own.","id_on_source":"recnac1","tweeter_id":"237468540","geo":{"lt":null,"ln":null},"followers":1105},"tweet_id":"560158796266209280"},{"url":"https:\/\/twitter.com\/GoToPER\/status\/557862895263158272","license":"datasift","citation_ids":[3086080],"posted_on":"2015-01-21T11:30:53+00:00","author":{"name":"PER","url":"http:\/\/gotoper.com","image":"https:\/\/pbs.twimg.com\/profile_images\/3438723869\/2416df847bccb4c5ad8da6015ba30370_normal.jpeg","description":"Physicians' Education Resource (PER) specializes in oncology and hematology CME-certified activities. We advance cancer care through professional education.","id_on_source":"GoToPER","tweeter_id":"37703552","geo":{"lt":40.31622,"ln":-74.51376,"country":"US"},"followers":4420},"tweet_id":"557862895263158272"}],"news":[{"title":"Low LDH May Predict Second-Line Bevacizumab CRC Response","url":"http:\/\/ct.moreover.com\/?a=27181907857&p=1pl&v=1&x=SNcT_gTbsBeMj8iTh1f6KA","license":"public","citation_ids":[3086080],"posted_on":"2016-07-07T20:41:17+00:00","summary":"BARCELONA \u2014 Patients with metastatic colorectal cancer (CRC) who have progressed after first-line chemotherapy plus bevacizumab ( Avastin, Genentech) and who have low levels of lactate dehydrogenase (LDH) may benefit from continuation of\u2026","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}},{"title":"Reduce Cancer Care Costs by Avoiding 'Low-Value' Options","url":"http:\/\/ct.moreover.com\/?a=29983076172&p=1pl&v=1&x=7bvK-UEAQPB4unDGIwL2xQ","license":"public","citation_ids":[17410462,3086080,4010036,228841,3066003,3066004,1799290,14866056,542676,9931126],"posted_on":"2017-03-22T15:14:57+00:00","summary":"Oncologists can help reduce the costs of treating cancer by favoring drug regimens that have proven value over more expensive alternatives, especially when evidence supporting many of these alternatives is weak, an opinion piece by Bishal Gyawali, MD\u2026","author":{"name":"Medscape","url":"http:\/\/medscape.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/055\/normal\/medscape.png?1369846939"}}]}}